Adaptive Biotechnologies Corp
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
ADPT$30.26+8.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net loss | $(59,457) | $(159,595) | $(225,304) |
| Other comprehensive income (loss) | |||
| Change in unrealized gains and losses on investments | 87 | (49) | 4,331 |
| Comprehensive loss | (59,370) | (159,644) | (220,973) |
| Add: Comprehensive (income) loss attributable to noncontrolling interest | (42) | 103 | 54 |
| Comprehensive loss attributable to Adaptive Biotechnologies Corporation | $(59,412) | $(159,541) | $(220,919) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.